ABI-2280

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameABI-2280
Drug Alias Nameprodrug of an acyclic nucleoside phosphonateABI-2280
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionVirus replication inhibitorsApoptosis stimulants
TargetsNot applicable
Therapy Area/IndicationsCervical Intraepithelial NeoplasiaPapillomavirus InfectionsInfections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMexicoSouth Africa +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAntiva Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAntiva Biosciences Inc
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsCervical Intraepithelial NeoplasiaInfections

Other Information

ATC CodeN/A
Related LinksN/A